LabTurbo Biotech Corporation (7725.TWO)
TWD 25.0
(-8.59%)
TWD 25.0
(-8.59%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -149.58 Million | 861.33 Million | 255.52 Million |
| Net Income | -55.23 Million | 822.67 Million | 578.68 Million |
| Depreciation & Amortization | 46.19 Million | 41.79 Million | 20.23 Million |
| Deferred income taxes | - | - | - |
| Stock-based compensation | - | - | 210 Thousand |
| Change in working capital | 72.82 Million | 164.82 Million | -320.22 Million |
| Other non-cash items | -6.12 Million | -702 Thousand | 560 Thousand |
| Investing Cash Flow | -94.6 Million | -578.79 Million | -34.38 Million |
| Investments in PPE | -26.72 Million | -59.95 Million | -124.32 Million |
| Acquisitions | -27.7 Million | - | 23.69 Million |
| Investment purchases | -865.28 Million | -812.96 Million | - |
| Sales/Maturities of investments | 752.32 Million | 295.24 Million | 79.74 Million |
| Other Investing Activities | 13.76 Million | -18.69 Million | -13.49 Million |
| Financing Cash Flow | -176.99 Million | -172.9 Million | 203.93 Million |
| Debt repayment | -24.73 Million | -21.9 Million | -20.35 Million |
| Dividends payments | -144.98 Million | -144.98 Million | -18.93 Million |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | - | - | 244.8 Million |
| Other Financing Activities | -241 Thousand | -470 Thousand | 577 Thousand |
| Accounts receivables | 90.25 Million | - | - |
| Accounts payables | - | - | - |
| Inventory | 29.29 Million | -23.05 Million | -18.55 Million |
| Other working capital | -46.72 Million | - | - |
| Cash at beginning of period | 714.04 Million | 604.72 Million | 179.81 Million |
| Cash at end of period | 294.02 Million | 714.04 Million | 604.72 Million |
| Capital Expenditure | -26.72 Million | -59.95 Million | -124.32 Million |
| Effect of forex changes on cash | 1.16 Million | -317 Thousand | -178 Thousand |
| Net cash flow / Change in cash | -420.02 Million | 109.32 Million | 424.91 Million |
| Free Cash Flow | -176.31 Million | 801.38 Million | 131.2 Million |
| Breakdown | 2023 FY | 2022 FY | 2021 FY |
|---|---|---|---|
| Operating Cash Flow | - | - | - |
| Net Income | -55.23 Million | 822.67 Million | 578.68 Million |
| Depreciation & Amortization | 46.19 Million | 41.79 Million | 20.23 Million |
| Deferred income taxes | - | - | - |
| Stock-based compensation | - | - | 210 Thousand |
| Change in working capital | 72.82 Million | 164.82 Million | -320.22 Million |
| Other non-cash items | -6.12 Million | -702 Thousand | 560 Thousand |
| Investing Cash Flow | -94.6 Million | -578.79 Million | -34.38 Million |
| Investments in PPE | -26.72 Million | -59.95 Million | -124.32 Million |
| Acquisitions | -27.7 Million | - | 23.69 Million |
| Investment purchases | -865.28 Million | -812.96 Million | - |
| Sales/Maturities of investments | 752.32 Million | 295.24 Million | 79.74 Million |
| Other Investing Activities | 13.76 Million | -18.69 Million | -13.49 Million |
| Financing Cash Flow | -176.99 Million | -172.9 Million | 203.93 Million |
| Debt repayment | -24.73 Million | -21.9 Million | -20.35 Million |
| Dividends payments | -144.98 Million | -144.98 Million | -18.93 Million |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | - | - | 244.8 Million |
| Other Financing Activities | -241 Thousand | -470 Thousand | 577 Thousand |
| Accounts receivables | - | - | - |
| Accounts payables | - | - | - |
| Inventory | 29.29 Million | -23.05 Million | -18.55 Million |
| Other working capital | - | - | - |
| Cash at beginning of period | 714.04 Million | 604.72 Million | 179.81 Million |
| Cash at end of period | 294.02 Million | 714.04 Million | 604.72 Million |
| Capital Expenditure | -26.72 Million | -59.95 Million | -124.32 Million |
| Effect of forex changes on cash | 1.16 Million | -317 Thousand | -178 Thousand |
| Net cash flow / Change in cash | -420.02 Million | 109.32 Million | 424.91 Million |
| Free Cash Flow | -176.31 Million | 801.38 Million | 131.2 Million |
GGDVF
1773
GBBYF
NORCO
NOUV
DMCD